MarsLight-11

CIBI363C301/MarsLight-11 A Randomized, Open-Label, Multi-Center, Phase 3 Study Evaluating the Efficacy and Safety of IBI363 Versus Docetaxel in Participants with Unresectable Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer with Disease Progression on or After Platinum-Based Chemotherapy and AntiPD-1/PD-L1 Immunotherapy